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S U M M A R Y
Objectives: To describe the epidemiology, antimicrobial susceptibilities, treatment, and outcomes of
intensive care unit (ICU)-acquired Gram-negative bacteremia.
Methods: Patients with ICU-acquired Gram-negative bacteremia from 2004 to 2012 were reviewed
retrospectively. Independent predictors of mortality were examined using multivariable Cox regression.
Results: Seventy-eight cases of ICU-acquired Gram-negative bacteremia occurred in 74 patients. The
infection rate was 0.97/1000 patient-days. Mean patient age was 55 years, 62% were male. The most
common admission diagnoses were respiratory failure (34%) and sepsis/septic shock (45%). Mortality
was 35% at 30 days. The most common source of bacteremia was pneumonia (33%). Of 83 Gram-negative
isolates, Escherichia coli (20%) and Pseudomonas aeruginosa (18%) were most common. For aerobic
isolates, susceptibilities to ciproﬂoxacin (61%) and piperacillin/tazobactam (68%) were low. For
pseudomonal isolates, susceptibilities to ciproﬂoxacin (53%), piperacillin/tazobactam (67%), and
imipenem (53%) were equally disappointing. Adequate empiric antimicrobial therapy was prescribed
in 85% of bacteremia cases. On multivariable analysis, adequate empiric therapy (adjusted hazard ratio
(aHR) 0.38, 95% conﬁdence interval (CI) 0.16–0.89), immune suppression (aHR 3.4, 95% CI 1.4–8.3), and
coronary artery disease (aHR 4.5, 95% CI 1.7–11.9) were independently associated with 30-day mortality.
Conclusions: ICU-acquired Gram-negative bacteremia is associated with high mortality. Resistance to
ciproﬂoxacin, piperacillin/tazobactam, and carbapenems was common. Coronary artery disease,
immune suppression, and inadequate empiric antimicrobial therapy were independently associated
with increased mortality.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Despite considerable preventative efforts, hospital-acquired
infections continue to contribute to substantial morbidity and
mortality,1 occurring in approximately 4% of hospitalized
patients.2 An estimated 250 000 nosocomial bloodstream infec-
tions occur each year in the USA,3 with approximately 30% due to
Gram-negative bacilli. Mortality rates in Gram-negative sepsis are
high, and can be up to 50% depending on patient factors, as well as
timing and appropriateness of empiric antimicrobial therapy.4–7* Corresponding author. Tel.: +1 780-492-8311; fax: +1 780-492-1500.
E-mail address: wsligl@ualberta.ca (W.I. Sligl).
http://dx.doi.org/10.1016/j.ijid.2015.06.024
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Although intensive care units (ICUs) account for less than 10% of
the total number of beds in most hospitals, more than 20–30% of all
nosocomial infections are acquired in the ICU,2,8 with high rates of
antimicrobial resistance9,10 and mortality7,11 when compared with
the general hospital population. Understanding the local epidemi-
ology and antimicrobial susceptibility patterns in ICU-acquired
Gram-negative bacteremia may facilitate the development of
empiric therapy guidelines, formulary restrictions, and/or antimi-
crobial stewardship programs, resulting in improved patient
outcomes.
The aim of this study was to provide up-to-date data on the
epidemiology (including incidence, source, microbial etiology,
antimicrobial susceptibilities, and outcomes) of nosocomial Gram-
negative bacteremia in a population of critically ill patients. A
comparison of rates, microbiology, antimicrobial susceptibilities,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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performed, in particular a comparison to data published previously
from the same patient population.12
2. Materials and methods
A retrospective observational cohort study was conducted at
the University of Alberta Hospital, a 650-bed academic quaternary
care referral hospital in Edmonton, Canada and the principal
teaching hospital of the University of Alberta, Faculty of Medicine
and Dentistry. It is a level-one trauma center, the largest solid
organ transplantation center in Western Canada, and has a referral
area of over two million.
The University of Alberta Hospital contains a 32-bed adult
general systems ICU that admits general medical, surgical, trauma,
and solid organ transplant patients. The ICU provides general
invasive hemodynamic monitoring and support, mechanical
ventilation, and renal replacement therapy, as well as extracorpo-
real liver support. Other specialized support therapies such as
extracorporeal membrane oxygenation (ECMO) are provided in the
cardiovascular ICU.
This study was conducted as part of a quality improvement
study through Infection Prevention and Control and was therefore
exempt from ethics submission as per the Research Ethics Board at
the University of Alberta. Infection Prevention and Control (IPC)
monitors all inpatient populations prospectively, including ICU
patients, for the development of nosocomial infection(s). Positive
blood cultures are identiﬁed by the clinical microbiology
laboratory (BACTEC 9240 Blood Culture System; Becton Dickinson
Biosciences) and reviewed by IPC daily. Charts are subsequently
reviewed and blood culture isolates categorized as contaminants,
community-acquired, or nosocomial using standardized US
Centers for Disease Control and Prevention/National Healthcare
Safety Network (CDC/NHSN) criteria.13 For nosocomial bacteremia,
the originating source is then identiﬁed and subcategorized.
All cases of ICU-acquired Gram-negative bacteremia from
January 1, 2004 to December 31, 2012 were reviewed. Demo-
graphic data, the source of bacteremia, causative microorganisms,
antimicrobial susceptibilities, choice of empiric antibiotic therapy,
ICU and hospital lengths of stay (LOS), and 30-day mortality rates
were collected. Data were subsequently compared to previously
published data for the period 1999–2003 in the same patient
population.12
Immune compromise was deﬁned as chronic steroid use (daily
equivalent of 20 mg prednisone for 1 month per year), solid organ
or hematopoietic stem cell transplantation, receipt of chemother-
apy within the previous month, neutropenia (absolute neutrophil
count <1.0  109 cells/L) at the time of admission, or HIV/AIDS
(CD4 count <200 cells/ml). End-stage renal disease (ESRD) was
deﬁned as kidney failure necessitating either peritoneal or
intermittent hemodialysis prior to admission. Empiric therapy
was deemed effective if treatment was with an agent to which the
microorganism was ultimately susceptible. Multi-drug resistance
in Pseudomonas species was deﬁned as resistance to three or more
ﬁrst-line antimicrobials in the following classes: b-lactams,
carbapenems, aminoglycosides (AGs), and ﬂuoroquinolones.
2.1. Statistical analysis
Epidemiological data were reported, including descriptive
statistics such as proportions, percentages, means, and medians.
Characteristics of subjects who died and survived were compared
using the t-test or Mann–Whitney U-test (as appropriate based on
their distribution) for continuous variables. The Chi-square test or
Fisher’s exact test was used for categorical variables.Kaplan–Meier survival curves were then constructed and log-
rank tests performed for variables associated with mortality on
univariate analysis.
Multivariable Cox regression modeling was subsequently
performed to identify variables independently associated with
30-day mortality. The APACHE II score (Acute Physiology and
Chronic Health Evaluation) was included for clinical signiﬁcance.
Otherwise variables identiﬁed to be signiﬁcantly associated with
increased mortality (p < 0.1) on univariate analysis were entered
into the model. There were no proportional hazards violations,
which were tested using time covariate interaction terms. Results
are presented as adjusted hazard ratios (aHR) and 95% conﬁdence
intervals (CI). All statistical tests were two-sided and p-values of
<0.05 were considered statistically signiﬁcant.
Statistical analyses were performed using IBM SPSS Statistics
for Windows, version 22.0 (IBM Corp., Armonk, NY, USA).
3. Results
There were 11 602 admissions to the general systems ICU from
January 1, 2004 to December 31, 2012. A total of 78 episodes of ICU-
acquired Gram-negative bacteremia occurred in 74 patients, result-
ing in an overall infection rate of 6.7 per 1000 ICU admissions, or
9.7 per 10 000 patient-days. These rates are similar to those observed
in the previous study (6.9 per 1000 ICU admissions and 11.3 per
10 000 patient-days). Annual infection rates ﬂuctuated by year from
1.6 to 9.6 per 1000 admissions and 2.3 to 15.0 per 10 000 patient-
days, consistent with expected year-to-year variation.
The mean patient age was 55 years (range 18–85, standard
deviation (SD) 15.8 years) and 46/74 (62.2%) were male. A large
number of patients (26/74, 35%) were immune compromised.
Additional speciﬁc patient demographics can be found in Table 1.
The majority of patients were admitted with medical diagnoses
(51/72, 69%). Admitting diagnoses included respiratory failure (25/
74, 34%), sepsis or septic shock (33/74, 45%), liver transplantation
(7/74, 10%), and trauma/major burns (5/75, 7%). The mean APACHE
II score was 25 (SD 8.3) at the time of admission, and 73/78 (94%)
patients required invasive mechanical ventilation.
The most common source of bacteremia was pneumonia, in 26/
78 (33%) patients, as was observed in the previous study. Other
common sources included gastrointestinal tract infections (not
endoscopy-related) (17/78, 22%) and catheter-related bloodstream
infections (10/78, 13%) (Figure 1). A decrease in catheter-related
bloodstream infections was observed from 1999–2003 to 2004–
2012 (22% vs. 13%, respectively).
Bacterial species identiﬁed can be found in Figure 2. In
summary, the most common bacterial pathogen was Escherichia
coli (17/83, 21%), followed by Pseudomonas aeruginosa (15/83, 18%)
and Klebsiella species (13/83, 16%).
The majority of isolates were aerobic Gram-negative bacilli (71/
83, 86%), of which 49/83 (59%) were Enterobacteriaceae. Glucose
non-fermenting organisms (Pseudomonas and Stenotrophomo-
nas) accounted for 21/83 (25%) cases of bacteremia.
Multidrug-resistant (MDR) pathogens were isolated in 14/83
(17%) cases, including extended-spectrum b-lactamase producers
(ESBLs; 5/83, 5%), carbapenem-resistant Enterobacteriaceae (CRE;
2/83, 2%), and MDR Pseudomonas (7/83, 8%).
The majority of infections were monomicrobial (63/78, 81%). In
15 polymicrobial infections, three were with another Gram-
negative organism, 10 with Gram-positive organisms, and there
were two events in which additional Gram-negative and Gram-
positive organisms were identiﬁed.
Overall aerobic Gram-negative and pseudomonal susceptibili-
ties are shown in Table 2. Of all aerobic isolates tested,
susceptibilities to ciproﬂoxacin (40/66, 61%) and piperacillin/
tazobactam (44/65, 68%) were low. Similar numbers were observed
Table 1
Baseline characteristics (N = 74)a
Variables No. (%)
Age, years, mean (SD) 55 (16)





Chronic lung disease 12 (16)
COPD 7 (10)
Pulmonary ﬁbrosis 2 (3)
Asthma 2 (3)
Bronchiectasis 2 (3)
Neuromuscular disease 1 (1)
Diabetes mellitus 18 (24)
ESLD 19 (26)
HCV infection 8 (11)
Autoimmune hepatitis 4 (5)
Alcoholic liver disease 11 (15)
Primary sclerosing cholangitis 2 (3)
Coronary artery disease 9 (12)
Hypertension 15 (20)
Congestive heart failure 5 (7)
Atrial ﬁbrillation 7 (10)
Malignancy 12 (16)





Solid organ transplant 19 (26)
Liver transplant 13 (18)
Lung transplant 1 (1)
Heart transplant 2 (3)
Renal transplant 3 (4)
ESRD 5 (7)
Psychiatric disease 8 (11)
Admission diagnosis
Respiratory failure 25 (34)
Sepsis or septic shock 33 (45)
Liver transplantation 7 (10)
Trauma or major burn 5 (7)
APACHE II score, mean (SD) 25 (8)
ICU LOS, median (IQR) 20.5 (7–33)
Hospital LOS, median (IQR) 50 (25–109)
30-day mortality 26 (35)
Hospital mortality 36 (49)
SD, standard deviation; COPD, chronic obstructive pulmonary
disorder; ESLD, end-stage liver disease; HCV, hepatitis C virus;
HIV, human immunodeﬁciency virus; AIDS, acquired immuno-
deﬁciency syndrome; ESRD, end-stage renal disease; APACHE,
Acute Physiology and Chronic Health Evaluation; ICU, intensive
care unit; LOS, length of stay; IQR, interquartile range.
a Data are presented as percentage of all isolates.
Figure 1. Sources of bacteremia.
Figure 2. Microbial isolates.
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bility to ciproﬂoxacin (8/15, 53%), piperacillin/tazobactam (10/15,
67%), and imipenem (8/15, 53%) were equally disappointing.
Changes in antimicrobial susceptibilities over time are demon-
strated in Figure 3. Comparison of the two study periods
demonstrated the following: (1) sustained resistance to ciproﬂox-
acin in 30–50% of isolates (in aerobic isolates as well as
Pseudomonas alone), (2) increased resistance to piperacillin/
tazobactam in aerobic isolates (from 11% to 32%) and in
pseudomonal isolates alone (0% to 33%), and (3) substantially
increased carbapenem resistance in Pseudomonas (9% to 47% for
imipenem). Surprisingly, only 2/6 (33%) strains of Stenotrophomo-
nas maltophilia were susceptible to trimethoprim/sulfamethoxa-
zole (TMP/SMX).
Empiric therapy was appropriate in 66/78 (85%) cases of aerobic
Gram-negative bacteremia and 11/15 (73%) cases of pseudomonalbacteremia. The most commonly prescribed empiric antibiotics
were piperacillin/tazobactam (31/78, 40%) and anti-pseudomonal
carbapenems (29/78, 37%). After excluding cases of S. maltophilia,
for which empiric therapy is not common or standard of care,
effective empiric coverage increased to 63/72 (88%). In the six cases
of S. maltophilia bacteremia, three (50%) patients received adequate
empiric therapy.
The crude 30-day mortality was 35% (26/74) and hospital
mortality was 49% (36/74). Data from the previous study
demonstrated higher mortality rates (53% and 60%, respectively).
Comparing rates over time, there was a trend to decreased 30-day
mortality only (p = 0.07) (p = 0.3 for in-hospital mortality). The
median ICU LOS was 20.5 days (interquartile range (IQR) 7–33
days), while hospital LOS was substantially longer (49.5 days, IQR
25.3–109 days). Median ICU LOS following the ﬁrst date of
bacteremia was 6.5 days (IQR 2–20 days).
On univariate analysis (see Table 3), immune suppression,
steroid use, and adequate empiric antimicrobial therapy were
associated with mortality. A trend towards increased mortality
with pseudomonal bacteremia and coronary artery disease was
observed.
On multivariable analysis (see Table 4), adequate empiric
antimicrobial therapy (aHR 0.38, 95% CI 0.16–0.89; p = 0.03),
immune suppression (aHR 3.44, 95% CI 1.43–8.27; p = 0.006), and
coronary artery disease (aHR 4.48, 95% CI 1.70–11.85; p = 0.003)
were associated with 30-day mortality.
Table 3
Univariate analysis of 30-day mortality (78 bacteremic events)a
Variable 30-day mortality
Alive Dead p-Value
n = 51 (65) n = 27 (35) (Chi-square)
Age, in years, mean (SD) 54 (16) 56 (16) 0.8
Male sex 31 (61) 16 (60) 0.9
Admission class 0.7
Medical 34 (67) 19 (70)
Surgical 17 (33) 8 (30)
Comorbidities
Chronic lung disease 7 (14) 5 (18) 0.7
COPD 5 (10) 2 (7) 1.0
Pulmonary ﬁbrosis 1 (2) 1 (4) 0.6
Asthma 1 (2) 1 (4) 1.0
Bronchiectasis 1 (2) 1 (4) 1.0
Neuromuscular disease 1 (2) 0 (0) 1.0
Diabetes mellitus 14 (28) 5 (19) 0.4
ESLD 14 (28) 6 (22) 0.6
HCV infection 6 (12) 2 (7) 0.7
Autoimmune hepatitis 2 (4) 3 (11) 0.3
Alcoholic liver disease 6 (12) 5 (19) 0.5
Primary sclerosing
cholangitis
2 (4) 0 (0) 0.5
Coronary artery disease 3 (6) 6 (22) 0.06b
Hypertension 8 (16) 8 (30) 0.2
Congestive heart failure 2 (4) 3 (11) 0.3
Atrial ﬁbrillation 4 (8) 3 (11) 0.7
Malignancy 7 (14) 5 (19) 0.7
Immune suppression 13 (26) 15 (56) 0.01b
Steroids 1 (2) 4 (15) 0.046b
Chemotherapy 2 (4) 3 (11) 0.3
Neutropenia 1 (2) 2 (7) 0.3
HIV/AIDS 2 (4) 1 (4) 1.0
Transplant 12 (24) 8 (30) 0.6
Liver transplant 11 (22) 3 (11) 0.4
Lung transplant 0 (0) 1 (4) 0.4
Table 2
Antimicrobial susceptibilities (No. (%))
Susceptible Intermediate Resistant
Aerobic isolates (n = 71)
Ceftriaxone (n = 53) 37 (70) 1 (2) 15 (28)
Ciproﬂoxacin (n = 66) 40 (61) 2 (3) 24 (36)
Gentamicin (n = 66) 53 (80) 2 (3) 11 (17)
Meropenem (n = 55) 46 (84) 0 (0) 9 (16)
Imipenem (n = 58) 47 (81) 1 (1) 10 (17)
Piperacillin/tazobactam
(n = 65)
44 (68) 1 (2) 20 (31)
Tobramycin (n = 63) 49 (78) 3 (5) 11 (18)
Pseudomonas aeruginosa
(n = 15)
Ceftazidime (n = 15) 11 (73) 1 (7) 3 (20)
Cefepime (n = 5) 2 (40) 1 (20) 2 (40)
Ciproﬂoxacin (n = 15) 8 (53) 1 (7) 6 (40)
Gentamicin (n = 15) 9 (60) 2 (13) 4 (27)
Meropenem (n = 12) 7 (58) 0 (0) 5 (42)
Imipenem (n = 15) 8 (53) 1 (7) 6 (40)
Piperacillin/tazobactam
(n = 15)
10 (67) 0 (0) 5 (33)
Tobramycin (n = 15) 11 (73) 1 (7) 3 (20)
Amikacin (n = 15) 13 (87) 0 (0) 2 (13)
Aztreonam (n = 10) 4 (40) 1 (10) 5 (50)
Colistin (n = 4) 4 (100) 0 (0) 0 (0)
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The incidence of ICU-acquired Gram-negative bacteremia in our
general systems ICU has been stable over the past 14 years.
Catheter-related bloodstream infections, however, have decreased
over time, likely due to major preventative efforts (zero tolerance),
including a prevention bundle introduced in 2006, as well as
increased education and awareness.Figure 3. Comparison of antimicrobial susceptibilities over time: (a) aerobic
isolates; (b) pseudomonal isolates.
Heart transplant 1 (2) 1 (4) 1.0
Renal transplant 1 (2) 2 (7) 0.3
ESRD 4 (8) 2 (7) 1.0
Psychiatric disease 6 (12) 2 (7) 0.7
Admission diagnosis
Respiratory failure 16 (31) 10 (37) 0.6
Sepsis or septic shock 20 (39) 14 (52) 0.3
Liver transplantation 7 (14) 1 (4) 0.3
Trauma or major burn 4 (8) 1 (4) 0.4
APACHE II score, mean (SD) 24 (8) 26 (9) 0.8
Pseudomonal bacteremia 7 (14) 8 (30) 0.09b
Adequate empiric therapy 47 (92) 19 (70) 0.01b
SD, standard deviation; COPD, chronic obstructive pulmonary disorder; ESLD, end-
stage liver disease; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus;
AIDS, acquired immunodeﬁciency syndrome; ESRD, end-stage renal disease;
APACHE, Acute Physiology and Chronic Health Evaluation.
a Results are given as the number and percentage (No. (%)), unless stated otherwise.
b Signiﬁcant, p < 0.05.Similar to the previous study by this group, a large cohort of
immune suppressed patients was identiﬁed, which is not
surprising for a quaternary care ICU with expertise in solid organ
transplantation. In fact 13/74 (18%) patients were postoperative
liver transplant recipients. In this subgroup, a higher risk-adjusted
mortality was demonstrated. Several studies have demonstrated
similarly poor outcomes in immunocompromised critically ill
patients who develop sepsis,1,14 including liver transplant patients
with Gram-negative sepsis.15,16
The most common source of ICU-acquired Gram-negative
bacteremia was pneumonia in both study periods, as has been
observed in a number of other studies.12,17,18 Consistently high
rates of pseudomonal infection (22% and 18% of all isolates for both
study periods) were also observed. MDR organisms were common
(17% of all isolates) and included ESBL producers, CREs, and MDR
pseudomonal infections.
Perhaps of most interest, antimicrobial susceptibility patterns
demonstrated persistent and increasing resistance over time.
Table 4
Multivariable regression analysis of 30-day mortality (78 bacteremic events)
Variable 30-day mortality
aHR (95% CI) p-Value
APACHE II score 1.00 (0.96–1.05) 0.9
Adequate empiric therapy 0.38 (0.16–0.89) 0.03a
Immune suppression 3.44 (1.43–8.27) 0.006a
Coronary artery disease 4.48 (1.70–11.85) 0.003a
Pseudomonal bacteremia 1.18 (0.48–2.90) 0.7
a HR, adjusted hazard ratio; CI, conﬁdence interval; APACHE, Acute Physiology
and Chronic Health Evaluation.
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isolates, making this drug an unattractive choice for empiric
therapy. Ciproﬂoxacin resistance in Pseudomonas has been
increasing steadily over the past decade due to high ﬂuoroquino-
lone use in both community and hospital settings,19,20 and
although recent studies suggest resistance may actually be
decreasing due to decreased ﬂuoroquinolone use,21 this was not
observed in the present data. Ciproﬂoxacin resistance among all
aerobic isolates (including the Enterobacteriaceae) was high,
essentially ruling out ciproﬂoxacin as an option for empiric
therapy in ICU-acquired Gram-negative bacteremia.
More concerning was the substantial increase in both piperacillin/
tazobactam and carbapenem resistance over time. This resistance
was demonstrated in all aerobic isolates as well as pseudomonal
isolates alone. Other studies have also demonstrated high rates of
carbapenem resistance in Enterobacteriaceae (predominantly Klebsi-
ella pneumoniae), as well as P. aeruginosa, which relates mainly to
prior patient antimicrobial exposure and also to unit antimicrobial
pressure.14,22,23 Although AGs demonstrated the highest activity
overall, substantial resistance to these agents was also observed, with
approximately 17% resistance among aerobic isolates and up to one
quarter resistance among pseudomonal isolates.
It is postulated that the increasing resistance observed may be
due to the widespread use, as well as longer than necessary, or even
unnecessary, courses of antimicrobial therapy in critically ill patients
in general. The use of piperacillin/tazobactam or anti-pseudomonal
carbapenems as empiric therapy in 77% of the cases presented herein
demonstrates that these are preferred agents in our institution. In
addition, the increasing incidence of MDR pathogens such as ESBLs
and CREs likely contributed to the observed increase in antimicrobial
resistance, as these organisms may be inherently resistant to speciﬁc
antimicrobials (e.g., ESBLs to piperacillin/tazobactam). The inci-
dence of drug-resistant Gram-negatives has become a global
problem for a number of reasons,24–26 particularly in ICUs, and will
pose more and more of a challenge in the future given the lack of
investment in antimicrobial research and development.
Despite increasing antimicrobial resistance, most patients
(85%) received appropriate empiric therapy. After excluding cases
of Stenotrophomonas, for which empiric therapy would not be
considered standard of care, even higher effective therapy rates
(88%) were observed. To compare, a recent study by Shorr et al.
observed lower (66%) rates of appropriate therapy in patients with
Gram-negative bacteremia and severe sepsis or septic shock.27
Nonetheless, 85% is still suboptimal, as 15% of patients received
ineffective empiric therapy for a serious, life-threatening infection.
The results of this study, however, serve to provide us with the
knowledge required to improve care. Effectiveness of empiric
therapy is indeed an important quality indicator; recent studies
have shown that both inadequate empiric therapies, as well as
delays in therapy, are associated with increased mortality.4,27–32
Based on the data presented here, empiric therapy with an AG in
addition to a carbapenem or ureidopenicillin is recommended for
ICU-acquired Gram-negative bacteremia in our centre. However, the
local epidemiology must be considered in each unit and empirictherapy prescribed based on local susceptibility patterns and patient
risk factors. Regarding the short-term safety proﬁle of AGs, the risk of
nephrotoxicity and ototoxicity is minimal if administered for 24–
48 h as a bridge to deﬁnitive therapy until susceptibility results are
available. Despite the low risk of toxicity with one to two doses,
many intensivists are still very reluctant to prescribe AGs even short-
term, particularly in patients presenting with acute kidney injury.
We would strongly argue that the risks of ineffective empiric therapy
in patients with ICU-acquired Gram-negative bacteremia far exceed
the risks of short-course AG therapy, and we would urge intensivists
to reconsider their prescribing practices. However, when prescribing
longer courses of AGs, which can result in toxicity due to cumulative
doses, a more careful evaluation of risks versus beneﬁts is necessary.
Once susceptibilities are conﬁrmed, it is also imperative to
narrow and discontinue antimicrobial therapy at the earliest time
possible to decrease adverse impacts on both the individual patient
(alterations in microbiome) and the unit microbial ecology. Data
from several studies suggest that restricting antimicrobial use,
with respect to duration and breadth, can decrease resistance
rates.33–35 Clearly, with increasing resistance this needs to be a
priority. The institution of antimicrobial stewardship programs can
be an effective way to decrease unnecessary and inappropriate
antibiotic use and should be instituted in all ICUs.36,37
The observed mortality rates remained high in this patient
population, with a 30-day mortality of 35%. However, when
compared to the previous data for the period 1999–2003 (30-day
mortality 53%), a substantial 18% reduction was observed, with a
trend to statistical signiﬁcance. This hopefully reﬂects improve-
ments in care, but it is recognized that this may also be due to any
number of confounders.
Independent predictors of mortality, identiﬁed on multivari-
able analysis, included coronary artery disease, immune suppres-
sion, and effective empiric antimicrobial therapy. Other studies
have demonstrated similar results,1,4,14,27–31,38 including a study
that demonstrated an association between reduced coronary ﬂow
reserve and mortality in sepsis.38 Despite an association on
univariate analysis, pseudomonal infection was not predictive of
mortality on multivariable analysis. This may be due to lack of
power given the relatively small sample size of the study, as
pseudomonal infection has clearly been associated with inferior
outcomes in a number of studies.28,31
Lastly, it may seem surprising that APACHE II scores did not
correlate with mortality in this study; however it is important to
recognize that APACHE II scores were collected within the ﬁrst 24 h
of ICU admission, which was temporally distinct from the time of
ICU-acquired bacteremia (which by deﬁnition occurred >48 h after
ICU admission). So although the APACHE II score was included in
the model for exploratory purposes (as it captures chronic as well
as acute disease), the lack of association was not surprising.
Despite some strengths of this study, several limitations are
also recognized. First, all observational data are inherently at risk
of confounding even with rigorous risk adjustment. In this study,
the number of bacteremic events was small (78 total events) with
only 26 deaths at 30 days, thus there were limitations in the ability
to risk-adjust and the study may have been underpowered to
detect predictors of mortality. The small size of the study also
limited the ability to perform sensitivity analyses. For example,
analyses in speciﬁc subgroups such as those with immune
suppression, septic shock, or speciﬁc microbial etiologies, were
not feasible. Although this is a weakness of the study, we are proud
to report so few nosocomial bloodstream infections over the past
decade, as this reﬂects high quality care provided in our institution.
Second, empiric therapy was deemed to be adequate if
treatment was prescribed with an effective agent once positive
blood culture results were reported (all results are called directly
to the bedside nurse at our institution); however actual
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effective antimicrobial administration have been associated with
poor outcomes in a number of studies,27,30–32,39,40 and clearly
could have confounded the present results. In addition, speciﬁc
doses of empiric antimicrobial therapies were not collected.
Antimicrobial under-dosing (due to obesity or inaccurate estima-
tion of creatinine clearance), for example, may have occurred and
altered patient outcomes. Lastly, the single-center design also
limits generalizability of the results, particularly given the high
proportion of immune suppressed (predominantly solid organ
transplant) patients in the population presented.
In conclusion, ICU-acquired Gram-negative bacteremia is
associated with high mortality. The most common source of ICU-
acquired Gram-negative bacteremia continues to be pneumonia.
Resistance to ciproﬂoxacin remains high, while resistance to
piperacillin/tazobactam has increased substantially over the past
decade. A substantial increase in carbapenem resistance in
Pseudomonas aeruginosa was also observed. Despite increasing
antimicrobial resistance, most patients received adequate empiric
antimicrobial therapy. It is suggested that empiric treatment
regimens be based on unit-speciﬁc data. Coronary artery disease,
immune suppression, and inadequate empiric antimicrobial therapy
were independently associated with increased 30-day mortality.
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